O	0	1	[
O	1	9	Efficacy
O	10	12	of
B-intervention	13	22	activated
I-intervention	23	31	charcoal
I-intervention	31	32	-
I-intervention	32	42	epirubicin
O	43	53	suspension
O	54	57	for
O	58	67	treatment
O	68	70	of
O	71	77	breast
O	78	84	cancer
O	85	89	with
O	90	98	axillary
O	99	109	metastasis
O	109	110	]
O	110	111	.

O	112	114	To
O	115	126	investigate
O	127	130	the
O	131	137	effect
O	138	140	of
O	141	150	activated
O	151	159	charcoal
O	159	160	-
O	160	170	epirubicin
O	171	181	suspension
O	182	183	(
O	183	186	Epi
O	186	187	-
O	187	189	CH
O	189	190	)
O	191	194	for
O	195	204	treatment
O	205	207	of
O	208	214	breast
O	215	221	cancer
O	222	225	and
O	226	235	clearance
O	236	238	of
O	239	247	axillary
O	248	253	lymph
O	254	258	node
O	259	269	metastasis
O	269	270	.

B-total-participants	271	276	Sixty
B-eligibility	277	285	patients
I-eligibility	286	290	with
I-eligibility	291	297	breast
I-eligibility	298	304	cancer
I-eligibility	305	307	of
I-eligibility	308	314	stages
I-eligibility	315	317	II
I-eligibility	317	318	-
I-eligibility	318	321	III
O	322	326	were
O	327	337	randomized
O	338	342	into
O	343	346	Epi
O	346	347	-
O	347	349	CH
O	350	355	group
O	356	357	(
O	357	358	n
O	358	359	=
B-intervention-participants	359	361	40
O	361	362	)
O	363	372	receiving
O	373	382	injection
O	383	387	with
O	388	390	10
O	391	393	mg
O	394	397	Epi
O	397	398	-
O	398	400	CH
O	401	403	in
O	404	407	the
O	408	414	tissue
O	415	421	around
O	422	425	the
O	426	433	primary
O	434	439	tumor
O	440	442	72
O	443	444	h
O	445	451	before
O	452	460	modified
O	461	468	radical
O	469	478	resection
O	479	482	and
O	483	490	control
O	491	496	group
O	497	498	(
O	498	499	n
O	499	500	=
B-control-participants	500	502	20
O	502	503	)
O	504	508	with
O	509	511	10
O	512	514	mg
O	515	517	of
B-control	518	525	aqueous
I-control	526	536	epirubicin
O	537	546	injection
O	547	549	in
O	550	553	the
O	554	558	same
O	559	565	region
O	565	566	.

O	567	570	The
O	571	580	dissected
O	581	589	axillary
O	590	595	lymph
O	596	601	nodes
O	602	605	and
O	606	609	the
O	610	618	staining
O	619	624	lymph
O	625	630	nodes
O	631	635	were
O	636	643	counted
O	643	644	.

O	645	648	The
O	649	662	concentration
O	663	665	of
O	666	676	epirubicin
O	677	679	in
O	680	683	the
O	684	689	lymph
O	690	695	nodes
O	696	699	was
O	700	708	detected
O	709	711	by
O	712	716	high
O	716	717	-
O	717	728	performance
O	729	735	liquid
O	736	747	chorography
O	747	748	,
O	749	752	and
O	753	756	the
O	757	766	specimens
O	767	769	of
O	770	775	lymph
O	776	781	nodes
O	782	786	were
O	787	795	observed
O	796	811	microscopically
O	811	812	.

O	813	815	In
O	816	826	comparison
O	827	831	with
O	832	835	the
O	836	843	control
O	844	849	group
O	849	850	,
O	851	854	Epi
O	854	855	-
O	855	857	CH
O	858	867	injection
O	868	875	allowed
O	876	886	dissection
O	887	889	of
O	890	891	4
O	891	892	.
O	892	894	04
O	895	899	more
O	900	905	lymph
O	906	911	nodes
O	912	913	(
O	913	914	P
O	914	915	<
O	915	916	0
O	916	917	.
O	917	919	01
O	919	920	)
O	921	924	and
O	925	933	resulted
O	934	936	in
O	937	940	the
B-outcome	941	949	staining
I-outcome	950	954	rate
I-outcome	955	957	of
I-outcome	958	961	the
I-outcome	962	970	axillary
I-outcome	971	976	lymph
O	977	982	nodes
O	983	985	of
B-iv-bin-percent	986	988	86
I-iv-bin-percent	988	989	.
I-iv-bin-percent	989	990	9
I-iv-bin-percent	990	991	%
O	992	993	(
B-iv-bin-abs	993	996	565
O	996	997	/
B-intervention-participants	997	1000	650
O	1000	1001	)
O	1001	1002	.

O	1003	1006	The
B-outcome	1007	1017	proportion
I-outcome	1018	1020	of
I-outcome	1021	1024	the
I-outcome	1025	1033	staining
I-outcome	1034	1039	lymph
I-outcome	1040	1045	nodes
I-outcome	1046	1050	with
I-outcome	1051	1059	diameter
I-outcome	1059	1060	>
I-outcome	1060	1061	1
I-outcome	1061	1062	.
I-outcome	1062	1063	0
I-outcome	1064	1066	cm
O	1067	1070	was
O	1071	1084	significantly
O	1085	1090	lower
O	1091	1095	than
O	1096	1100	that
O	1101	1105	with
O	1106	1114	diameter
O	1115	1116	<
O	1116	1118	or
O	1118	1119	=
O	1119	1120	1
O	1120	1121	.
O	1121	1122	0
O	1123	1125	cm
O	1126	1127	(
B-iv-bin-abs	1127	1129	96
O	1129	1130	/
B-intervention-participants	1130	1133	131
O	1134	1136	vs
B-cv-bin-abs	1137	1140	469
O	1140	1141	/
B-control-participants	1141	1144	519
O	1144	1145	,
O	1146	1147	P
O	1147	1148	<
O	1148	1149	0
O	1149	1150	.
O	1150	1152	01
O	1152	1153	)
O	1153	1154	.

O	1155	1158	The
B-outcome	1159	1169	metastatic
I-outcome	1170	1174	rate
I-outcome	1175	1177	of
I-outcome	1178	1185	stained
I-outcome	1186	1191	lymph
I-outcome	1192	1197	nodes
O	1198	1201	was
O	1202	1209	similar
O	1210	1214	with
O	1215	1219	that
O	1220	1222	in
O	1223	1226	non
O	1226	1227	-
O	1227	1234	stained
O	1235	1240	lymph
O	1241	1246	nodes
O	1247	1248	(
B-iv-bin-abs	1248	1251	214
O	1251	1252	/
B-intervention-participants	1252	1255	565
O	1256	1258	vs
B-cv-bin-abs	1259	1261	23
O	1261	1262	/
B-control-participants	1262	1264	85
O	1264	1265	,
O	1266	1267	P
O	1267	1268	>
O	1268	1269	0
O	1269	1270	.
O	1270	1272	05
O	1272	1273	)
O	1273	1274	.

O	1275	1277	In
O	1278	1281	Epi
O	1281	1282	-
O	1282	1284	CH
O	1285	1290	group
O	1290	1291	,
O	1292	1295	the
B-outcome	1296	1309	concentration
I-outcome	1310	1312	of
I-outcome	1313	1323	epirubicin
I-outcome	1324	1326	in
I-outcome	1327	1330	the
I-outcome	1331	1338	stained
I-outcome	1339	1344	lymph
I-outcome	1345	1350	nodes
O	1351	1354	was
O	1355	1368	significantly
O	1369	1375	higher
O	1376	1380	than
O	1381	1385	that
O	1386	1388	in
O	1389	1392	non
O	1392	1393	-
O	1393	1400	stained
O	1401	1405	ones
O	1406	1407	(
B-iv-cont-mean	1407	1410	443
I-iv-cont-mean	1410	1411	.
I-iv-cont-mean	1411	1412	0
O	1412	1413	-
O	1413	1414	/
O	1414	1415	+
B-iv-cont-sd	1415	1418	123
I-iv-cont-sd	1418	1419	.
I-iv-cont-sd	1419	1420	1
O	1421	1423	vs
B-cv-cont-mean	1424	1426	31
I-cv-cont-mean	1426	1427	.
I-cv-cont-mean	1427	1428	8
O	1428	1429	-
O	1429	1430	/
O	1430	1431	+
B-cv-cont-sd	1431	1433	11
I-cv-cont-sd	1433	1434	.
I-cv-cont-sd	1434	1435	9
I-cv-cont-sd	1436	1438	ng
I-cv-cont-sd	1438	1439	/
I-cv-cont-sd	1439	1440	g
O	1440	1441	,
O	1442	1443	P
O	1443	1444	<
O	1444	1445	0
O	1445	1446	.
O	1446	1448	01
O	1448	1449	)
O	1449	1450	.

O	1451	1461	Remarkable
B-outcome	1462	1474	degeneration
O	1475	1478	and
B-outcome	1479	1487	necrosis
O	1488	1493	could
O	1494	1496	be
O	1497	1505	observed
O	1506	1521	microscopically
O	1522	1524	in
O	1525	1528	the
O	1529	1536	stained
O	1537	1542	lymph
O	1543	1548	nodes
O	1548	1549	.

O	1550	1553	Epi
O	1553	1554	-
O	1554	1556	CH
O	1557	1563	allows
O	1564	1568	more
O	1569	1578	effective
O	1579	1588	treatment
O	1589	1591	of
O	1592	1598	breast
O	1599	1605	cancer
O	1606	1609	and
O	1610	1619	clearance
O	1620	1622	of
O	1623	1631	axiliary
O	1632	1642	metastasis
O	1643	1645	by
O	1646	1656	increasing
O	1657	1660	the
O	1661	1670	dissected
O	1671	1676	lymph
O	1677	1682	nodes
O	1683	1686	and
O	1687	1694	raising
O	1695	1698	the
O	1699	1712	concentration
O	1713	1715	of
O	1716	1726	epirubicin
O	1727	1729	in
O	1730	1733	the
O	1734	1742	axillary
O	1743	1748	lymph
O	1749	1754	nodes
O	1754	1755	.
